Reuters logo
BRIEF-Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine
August 4, 2017 / 10:51 AM / in 2 months

BRIEF-Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine

Aug 4 (Reuters) - Eli Lilly And Co:

* Eli Lilly announces positive results for second phase 3 study of Lasmiditan for the acute treatment of Migraine

* Lasmiditan met its primary endpoint in second phase 3 study spartan

* Greater percentage of patients treated with Lasmiditan were migraine pain-free compared to placebo

* Lasmiditan also met key secondary endpoint for spartan across all three studied doses

* Plan to submit new drug application for Lasmiditan to U.S. FDA in second half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below